Share
Babbage from The Economist
Babbage: Sex differences and sport
•
Some sports use different rules and equipment in the women’s game; some do not. We consider the distinction through the lenses of professional football and rugby. Scientific questions of relative performance lead to those of player safety, and ultimately to philosophy: what do varying opinions about changing women’s game reveal about the purpose of sport in society?
Arve Vorland Pedersen, a sports scientist at the Norwegian University of Science and Technology, calculates how football’s pitches and equipment might scale to account for physiological differences. Ross Tucker, a consultant for World Rugby, describes how a trial of a smaller ball might change the game’s mechanics. Lauren Heria, a professional footballer, explains why such meddling is seen as disrespectful by many players. And Emelia Funnell, a researcher at Ida Sports, reveals why ignorance about ACL injuries among women traces back to male cadavers. Host Alok Jha, The Economist’s science and technology editor, is joined by Abby Bertics, our science correspondent (and a former professional volleyball player).
For full access to The Economist’s print, digital and audio editions subscribe at economist.com/podcastoffer and sign up for our weekly science newsletter at economist.com/simplyscience.
More episodes
View all episodes
Low-energy cooling for a warming planet
32:02|In extreme heat, air-conditioning is a lifesaver. But it drives up energy bills, strains power grids, and fuels climate change. Is there a way to keep people cool indoors without making the outside world hotter? We explore some innovative engineering solutions.Guests and hosts:The Economist’s Nikita OstrovskyChris Trott and Saxbourne Cheung of Foster and PartnersAhmad Alduweesh and Jiayu Song of University College LondonAlex Hern, The Economist’s AI writerTopics covered:Air-conditioningPassive coolingGlobal warmingTranscripts of our podcasts are available via economist.com/podcasts.Listen to what matters most, from global politics and business to science and technology—subscribe to The Economist.
Why a wakefulness drug is pharma's latest obsession
35:23|A drug has been approved to treat narcolepsy, an excessive-sleepiness disorder. The new agonist mimics the action of orexin, a neurotransmitter which helps to keep people awake. Inspired by the success of GLP-1 diabetes-turned-weight-loss jabs, researchers hope that targeting the orexin system might one day help people with other brain-related ailments, too.Guests and hosts:Shailesh Chitnis, The Economist’s global business writerYanagisawa Masashi of the University of TsukubaGuy Leschziner of Guy’s and St Thomas’ Hospitals, LondonHarry Fagan of the University of SouthamptonAlex Hern, The Economist’s AI writerTopics covered:Orexin agonists and antagonistsSleep disordersPsychiatry Transcripts of our podcasts are available via economist.com/podcasts.Listen to what matters most, from global politics and business to science and technology—subscribe to The Economist.
Can robotaxis think more like humans?
39:54|How do you build an autonomous vehicle? Most self-driving car companies teach their models the rules of the road and pack cars with sophisticated sensors. But Wayve, a British startup, has a different approach. The company uses deep learning to train an “AI driver” for autonomous vehicles. In recent days, Wayve, in partnership with Uber, has been granted the first licences to operate robotaxis in London. Will their human-inspired cars finally transform city streets? We sit down with the company’s CEO, Alex Kendall, to find out. Guests and hosts:Alex Hern, The Economist’s AI writerAlex Kendall, CEO of WayveAlok Jha, The Economist’s science and technology editorWatch the full interview with Alex Kendall on The Economist’s “Inside Tech”.Topics covered:RobotaxisWayve and UberAutonomous vehicles Transcripts of our podcasts are available via economist.com/podcasts.Listen to what matters most, from global politics and business to science and technology—subscribe to The Economist.- 33:43|Red-light therapy has become a booming wellness trend. The long wavelengths of red and infrared light allow it to penetrate tissue, where it may be beneficial to cells. Beyond anti-ageing masks and infrared saunas, could exposure to red light become a serious tool in medicine? We meet the researchers investigating the potential effects—from improving eyesight to reducing blood sugar spikes and even helping with hard-to-treat neurological conditions. Guests and hosts:Sarah Lawrynuik, The Economist's audio correspondentGlen Jeffery of University College LondonDavid Davies and Mohammed Hadis of the University of Birmingham Alex Hern, The Economist’s AI writerTopics covered:Red-light therapyWellness trendsCell metabolismTranscripts of our podcasts are available via economist.com/podcasts.Listen to what matters most, from global politics and business to science and technology—subscribe to The Economist.
OpenAI’s alarming escape
38:16|AI is becoming harder to contain. Recently, OpenAI admitted that its model broke out of a testing environment to carry out an assault on Hugging Face, another AI firm. It was the first ever fully autonomous AI hack. OpenAI has now revealed its models have targeted other companies, too. What makes these incidents so worrying—and what will they mean for regulating AI?Guests and hosts:Nikita Ostrovsky of The EconomistAndrea Miotti, CEO of ControlAIAlex Hern, The Economist’s AI writerRead Alex’s exclusive conversation with Demis Hassabis about AI regulation on The Economist’s app. And, hear Elon Musk’s take on the topic on “The Intelligence” podcast.Topics covered:OpenAI’s Hugging Face hackSuperintelligent AIAI safety and regulationTranscripts of our podcasts are available via economist.com/podcasts.Listen to what matters most, from global politics and business to science and technology—subscribe to The Economist.
Earth is getting dimmer and hotter
37:40|Global dimming is making Earth hotter. Over the past few decades, the planet has been reflecting less sunlight and absorbing more heat, in ways that are confounding existing climate models. The reasons behind this dimming are still unclear but a surprising culprit is emerging—the welcome reduction in global air pollution. As Earth’s temperatures continue to break records this year, what does global dimming mean for future warming? Guests and hosts:Oliver Morton, planetary affairs editor at The EconomistAlok Jha, The Economist’s science and technology editor Topics covered:Global warming Albedo effectEarth’s energy imbalanceTranscripts of our podcasts are available via economist.com/podcasts.Listen to what matters most, from global politics and business to science and technology—subscribe to The Economist.
How Europe can compete on AI
39:30|Most of the world’s biggest AI firms are locked in a race to build “superintelligence”. But Mistral AI, a French frontier lab, is betting against this “winner-takes-all” competition. The firm thinks that smaller, more customisable, open-weight models will prove more valuable. Mistral’s boss outlines his plan—and why he thinks that, wherever you are, AI should be built and served closer to home. How does his vision stack up?Guests and hosts:Arthur Mensch, CEO of Mistral AIAlex Hern, The Economist’s AI writerAlok Jha, The Economist’s science and technology editor Watch Alex’s full interview with Arthur Mensch on The Economist’s “Inside Tech”.Topics covered:Mistral AIArtificial intelligenceOpen-source large language models Transcripts of our podcasts are available via economist.com/podcasts.Listen to what matters most, from global politics and business to science and technology—subscribe to The Economist.
A new era of biology beckons
39:29|Edith Heard worked out how the X chromosome works in women. She has spent decades leading thousands of scientists in trying to understand how the molecules in cells make organisms tick. At the European Molecular Biology Laboratory, she also helped usher in biology’s AI era, by helping Google DeepMind share its Nobel-prize-winning AlphaFold algorithm. Now she’s at the head of Europe’s biggest biomedical research institute—and is ready to tackle biology’s most difficult problems.Guests and hosts:Edith Heard, chief executive of the Francis Crick InstituteAlok Jha, The Economist’s science and technology editor Topics covered:EpigeneticsX-chromosome inactivationThe Francis Crick InstituteTranscripts of our podcasts are available via economist.com/podcasts.Listen to what matters most, from global politics and business to science and technology—subscribe to The Economist.
Should you get your baby’s genome sequenced?
37:59|Ainslie Johnstone, our science correspondent, is pregnant. When she was approached to have her newborn baby’s genome sequenced and screened for more than 200 rare conditions, she almost jumped at the opportunity. But she soon found herself with many unexpected questions. Guests and hosts:Ainslie Johnstone, data and science correspondent at The EconomistAmanda Pichini of Genomics EnglandEwan Birney of the European Bioinformatics InstituteAnneke Lucassen of the University of OxfordCarissa Véliz of the University of Oxford’s Institute for Ethics in AIAlok Jha, The Economist’s science and technology editor Topics covered:Genomic sequencingData securityThe Generation Study by Genomics EnglandTranscripts of our podcasts are available via economist.com/podcasts.Listen to what matters most, from global politics and business to science and technology—subscribe to The Economist.
